STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: A European patent has been granted for the use of nerve growth factors for the treatment of erectile dysfunction, also known as impotence. Diamyd Medical (STO:DIAMB) has an exclusive license for the patent, and patent applications have been filed in North America and Asia.
